• Recently discovered BRAF inhibitors may prevent drug-induced skin lesion side effects and lead to greater treatment durability. • Mechanism of drug-induced skin lesions is explored in preclinical model.
• VEGF and Ang2 are critical factors required for tumor angiogenesis. • Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. • Combination of REGN910 with aflibercept warrants further clinical investigation.
• Shutting down the ALK-1 receptor inhibits the VEGF pathway. • Response seen in patients who had used antiangiogenic therapy. • VEGF therapies might work best in combination.
• Phenotypic platform better predicts cancer drug effectiveness from the lab to actual tumors. • Platform reduces time and money spent on drugs that will not work or will be toxic. • Platform removes researcher bias in choosing systems to target for drug discovery.
1) Findings represent first evidence of ALK activity in inflammatory breast cancer. 2) Data emphasize importance of proteins and enzymes to define molecular biology. 3) Identification of ALK pathway activation could allow for more targeted treatment.
1) HDAC inhibitor first to show benefit in a controlled study in breast cancer. 2) Protein lysine acetylation linked to longer disease-free survival. 3) Study shows clinical gain can be determined after first or second dose of entinostat.
1) HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer. 2) Critical pathway by which tumors become tamoxifen resistant identified. 3) Early introduction of HDAC inhibitor with tamoxifen is key.
Underscoring the importance of a fully funded U.S. Food and Drug Administration in advancing progress in cancer, the American Association for Cancer Research calls on Congress to support the agency’s budget increase recently approved in the U.S. Senate.
Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics.
1) Therapy extended median survival to 6.4 months. 2) Two patients are alive four years after start of epigenetic treatment. 3) AACR will host teleconference on Nov. 9, 2011, at 11:00 a.m. ET.
1) Vaccine is a recombinant poxviral compound. 2) One patient with metastatic breast cancer had a sustained complete response.
1) Protein S100A10 is essential for metastatic growth. 2) Macrophages rely upon S100A10 to power movement of tumor cells to new sites.
Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF), along with the American Association for Cancer Research, call upon the cancer research community to submit Letters of Intent for a new Dream Team dedicated to prostate cancer research.
1) Erythorbate added to hot dogs reduced the content of possibly carcinogenic N-nitroso compounds. 2) Time trends in the incidence of colon cancer may not support the view that N-nitroso compounds in processed meat are a cause of colon cancer.
1) Drinking plenty of fluids reduced men’s risk for bladder cancer. 2) Men drank fewer liquids as they aged. 3) Physicians should feel comfortable recommending that patients drink plenty of low-sugar fluids.
1) Risk was further increased by being overweight, inactive lifestyle. 2) Dietary pattern may increase insulin resistance. 3) Altering diet could serve as colorectal cancer prevention method.
1) Use of aspirin was not associated with risk for renal cell cancer. 2) Acetaminophen and nonaspirin NSAID use increased risk. 3) Researchers observed similar risk trends for high-dose analgesics use.
1) A significantly inverse association was found for coffee consumption and basal cell carcinoma. 2) Decaffeinated coffee consumption was not associated with decreased risk. 3) Coffee consumption was not related to squamous cell carcinoma and melanoma.
1) Indoor tanning use increased risk for three common skin cancers. 2) Risk increased 11 percent to 15 percent with use every four times per year. 3) Risk effect was more predominant during high school/college.
1) Obesity in young adulthood was associated with risk for NHL later in life. 2) Obese men had a 64 percent higher risk for NHL compared with lean men. 3) Obese women had a 19 percent increased risk.
1) Significant difference found in the prevention of basal cell carcinoma. 2) Trend found in prevention of squamous cell carcinoma, although not significant. 3) No evidence of adverse effects found up to 10 years after being assigned to the drug.
1) Large amounts of weight gain increased risk twofold. 2) Increased risk was independent of body mass index. 3) Weight cycling, or “yo-yo” dieting, had no effect on endometrial cancer risk.
1) Lower colorectal cancer mortality rates were associated with consistent NSAID use at study enrollment and three years later. 2) Lower colorectal cancer mortality rates were associated with at least 10 years of reported NSAID use.
The AACR will present the 2011 AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research to Andrew J. Dannenberg, M.D., at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011.
Due to the high volume of sensitive fiduciary data in the abstracts for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, the embargo for all abstracts will lift at 10:00 a.m. PT, Sat., Nov. 12, 2011, when they are available to registrants in San Francisco and posted online.
1) Reductions of markers like PGE2 may be a biomarker for colon cancer prevention. 2) Phase II study conducted in humans requires validation. 3) Natural supplement use could be potential cancer prevention strategy.
• In 2008, there were 11.9 million cancer survivors. • This represents an almost fourfold increase since 1971, the year the National Cancer Act was signed. • Researchers expect a 42 percent increase in the number of older adult survivors in the next 10 years.
Conference to Highlight Advances in Cancer Drug Development, San Francisco, Calif., Nov. 12-16, 2011.
Conference to highlight advances in preventing cancer before it strikes.
1) A combination of P16 immunohistochemistry and viral DNA qPCR delivered solid results. 2) Diagnostic test may have immediate clinical impact. 3) Combination worked better than either individual test alone.
1) Even with no financial cost, screening rates are lower if negative attitudes persist. 2) Researchers tested rates of colorectal cancer screening rates in England. 3) Negative attitudes may be combated with psycho-educational interventions.
1) Current methods often fail to separate lethal from non-lethal cancers. 2) Levels of prostatic intraepithelial neoplasia (PIN) identify lethal cancers. 3) Men with PIN were 89 percent more likely to die of prostate cancer.
1) Race should be considered when recommending vitamin D supplementation. 2) Vitamin D deficiency has been linked to multiple diseases.
1) Pre-cancerous cells that consume sugar more common in this population. 2) Prediabetes or gestational diabetes could speed development of cancer cells.
1) Results based on lower-cost MRI screenings for high-risk, uninsured or under-insured women. 2) MRI screenings found more cancer cases in high-risk women than mammography. 3) Underserved women can benefit from follow-up with the help of a breast navigation team.
1) Differences could explain the higher rates of prostate cancer and mortality. 2) Understanding differences could lead to specialized treatment.
The American Association for Cancer Research will unveil the AACR Cancer Progress Report 2011 at 3:30 p.m. ET today during a press conference at the National Press Club. Dr. William S. Dalton, president and CEO of Moffitt Cancer Center, will be among the panel of experts to discuss the urgent need for support of cancer and biomedical research. The AACR is the world’s oldest and largest association dedicated to the acceleration of advances in cancer research for the prevention and cure of cancer.
INTEGRIS health official and cancer advocate Zora Brown’s story highlighted in report.
Advances in melanoma research cited in AACR report as case study of recent progress.
Josh Sommer, co-founder and executive director of the Chordoma Foundation, spoke at a star studded press conference to launch the AACR Cancer Progress Report 2011.
The AACR Cancer Progress Report 2011, released 40 years after the National Cancer Act was signed into law, comes at a critical time – when decades of fundamental knowledge about cancer have led to incredible scientific and technological breakthroughs. Yet due to the relatively flat funding at the National Institutes of Health (NIH) and the National Cancer Institute (NCI) since 2003, both the momentum gained and future progress of cancer research are now seriously threatened.
1) African ancestry linked to increased rates of high-risk disease. 2) Variants may be found in patients of any ethnic makeup.
1) Deaths from acute leukemia higher in blacks and Hispanics. 2) Racial disparity is greater in ALL than AML. 3) Reason unknown but researchers suspect socioeconomic factors.
1) Fear, anxiety and isolation were all linked with aggressive breast cancer. 2) Higher levels of psychosocial stress were reported in blacks and Hispanics.
1) Overall incidence of breast cancer is higher among white women. 2) 4 percent of women developed cancer in the opposite breast. 3) Physicians should carefully watch the opposite breast for signs of disease.
• Mammography rates among immigrant women in the U.S. increased from 60.2 percent in 2000 to 65.5 percent in 2008. • Immigrant women remain less likely than native-born U.S. women to be screened. • Increasing immigrant women’s access to insurance coverage may diminish disparity.
1) Few women underwent ovarian or colorectal screening. 2) One-third of the participants met the criteria for depression. 3) Depression linked to ovarian, but not colorectal screening noncompliance.
The American Association for Cancer Research will recognize leaders in the minority cancer community with the Minority-serving Institution Faculty Scholars in Cancer Research Awards. The seven recipients will be honored at the Fourth AACR Conference on The Science of Cancer Health Disparities, held Sept. 18-21, 2011, in Washington, D.C.
The American Association for Cancer Research will host its Fourth AACR Conference on The Science of Cancer Health Disparities from Sept. 18-21, 2011, in the Grand Hyatt Washington, located in Washington, D.C.
The American Association for Cancer Research is awarding 23 Minority Scholar in Cancer Research Awards at the Fourth AACR Conference on The Science of Cancer Health Disparities, held Sept. 18-21, 2011, in Washington, D.C.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right